# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform.
Wall Street experienced a quiet session during morning trading on Tuesday, influenced by a lack of significant economic data an...
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and raises the price...
HC Wainwright & Co. analyst Andrew Fein reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and maintains $462 pr...